Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
SWTX 
SpringWorks Therapeutics Inc (SWTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/27/2025: SWTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50.55% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/27/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.56B USD | Price to earnings Ratio - | 1Y Target Price 72.88 |
Price to earnings Ratio - | 1Y Target Price 72.88 | ||
Volume (30-day avg) 2398443 | Beta 0.76 | 52 Weeks Range 28.21 - 62.00 | Updated Date 03/27/2025 |
52 Weeks Range 28.21 - 62.00 | Updated Date 03/27/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.56 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -134.73% | Operating Margin (TTM) -132.16% |
Management Effectiveness
Return on Assets (TTM) -26.48% | Return on Equity (TTM) -46.62% |
Valuation
Trailing PE - | Forward PE 322.58 | Enterprise Value 3182945308 | Price to Sales(TTM) 18.57 |
Enterprise Value 3182945308 | Price to Sales(TTM) 18.57 | ||
Enterprise Value to Revenue 16.61 | Enterprise Value to EBITDA -7.9 | Shares Outstanding 74935800 | Shares Floating 73785893 |
Shares Outstanding 74935800 | Shares Floating 73785893 | ||
Percent Insiders 1.78 | Percent Institutions 115.71 |
Analyst Ratings
Rating 4.62 | Target Price 67.5 | Buy 3 | Strong Buy 5 |
Buy 3 | Strong Buy 5 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
SpringWorks Therapeutics Inc
Company Overview
History and Background
SpringWorks Therapeutics, Inc. was founded in 2017 as a spin-out from Pfizer Inc. It focuses on developing and commercializing medicines for underserved patient populations with cancer and rare diseases. The company's initial focus was on advancing a portfolio of oncology assets licensed from Pfizer.
Core Business Areas
- Oncology: Focuses on developing therapies for solid tumors, including desmoid tumors and other advanced cancers. Niermarket is a primary asset.
- Rare Diseases: Developing therapies for rare diseases with significant unmet medical needs, often in areas where there are limited or no approved treatments.
Leadership and Structure
Saqib Islam is the CEO. The organizational structure includes research and development, clinical operations, commercial, and administrative functions. The board of directors provides oversight and strategic guidance.
Top Products and Market Share
Key Offerings
- Ogsiveo (nirogacestat): Ogsiveo is approved for adult patients with desmoid tumors, progressive, nonresectable, or symptomatic. SpringWorks has a large share of the market as it's the first FDA-approved drug for desmoid tumors. Competitors include surgical resection, radiation, and systemic therapies like cytotoxic chemotherapy. In Q1 2024, Ogsiveo generated revenue of $101.3 million.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with companies developing and commercializing new therapies for a wide range of diseases. The market for oncology and rare disease drugs is growing due to aging populations and advances in genetic research.
Positioning
SpringWorks is positioned as a company focused on precision medicine for underserved patient populations. Its competitive advantage lies in its strong pipeline of targeted therapies and its ability to identify and develop treatments for rare diseases.
Total Addressable Market (TAM)
The TAM for desmoid tumors, is estimated to be $1.5B. SpringWorks is well positioned to capture a significant portion of this TAM.
Upturn SWOT Analysis
Strengths
- FDA-approved product (Ogsiveo)
- Strong pipeline of targeted therapies
- Experienced management team
- Focus on underserved patient populations
- Collaboration with Pfizer
Weaknesses
- Reliance on a limited number of products
- High R&D costs
- Dependence on successful clinical trials
- Limited commercial infrastructure compared to larger pharmaceutical companies
Opportunities
- Expanding the label for Ogsiveo
- Acquiring additional assets
- Partnering with other companies
- Developing new therapies for other rare diseases
- Global expansion
Threats
- Competition from other pharmaceutical companies
- Regulatory hurdles
- Patent expirations
- Pricing pressures
- Clinical trial failures
Competitors and Market Share
Key Competitors
- Other chemotherapies and treatments for desmoid tumors. There is no one publicly traded company that is a head on competitor.
- BMY
- MRK
Competitive Landscape
SpringWorks Therapeutics' advantage lies in having the only FDA approved drug for desmoid tumors. Other companies are pursuing treatment options.
Major Acquisitions
Seagen
- Year: 2023
- Acquisition Price (USD millions): 229
- Strategic Rationale: Acquired Seagenu2019s rights to develop and commercialize niraparib, furthering their oncology pipeline.
Growth Trajectory and Initiatives
Historical Growth: The company has experienced significant growth since its founding, driven by the development and commercialization of Ogsiveo.
Future Projections: Analysts project continued revenue growth for SpringWorks Therapeutics, driven by increased sales of Ogsiveo and the potential approval of additional therapies.
Recent Initiatives: Launching Ogsiveo, expanding its clinical pipeline, and exploring strategic partnerships are key initiatives.
Summary
SpringWorks Therapeutics is a growing biopharmaceutical company with a focus on underserved patient populations in oncology and rare diseases. The approval and launch of Ogsiveo for desmoid tumors represents a significant milestone. SpringWorks is well capitalized. Success depends on continued pipeline development and commercial execution of Ogsiveo, and managing competitive pressures.
Similar Companies
- GILD
- VRTX
- BLUE
- ALNY
Sources and Disclaimers
Data Sources:
- SpringWorks Therapeutics Inc. Investor Relations
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary. This analysis is based on publicly available information and analyst estimates.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About SpringWorks Therapeutics Inc
Exchange NASDAQ | Headquaters Stamford, CT, United States | ||
IPO Launch date 1987-06-05 | CEO & Director Mr. Saqib Islam J.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 368 | Website https://www.springworkstx.com |
Full time employees 368 | Website https://www.springworkstx.com | ||
SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. It offers OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor for the treatment of desmoid tumors; and GOMEKLI (mirdametinib), an oral small molecule inhibitor of MEK1 and MEK2 for the treatment of adult and pediatric patients two years of age and older with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The company also develops Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer; and mirdametinib for the treatment of solid tumors harboring other MAPK aberrations, including for the treatment of pediatric and young adult patients with low-grade gliomas that is in Phase 1/2 clinical trial. In addition, its products under development include Brimarafenib (BGB-3245), an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has license agreements with Pfizer Inc. for nirogacestat and mirdametinib; and Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.